In patients with recurrent glioblastoma (GBM) treated with anti-angiogenic therapy (AAT) (predominantly bevacizumab) plus chemotherapy, an increase in the numbers of CD11b+ myeloid cells, CD68+ total TAMs, and CD163+ M2-like TAMs was observed in autopsy specimens compared to initial diagnostic surgical specimens of the same patients [231]. The gene discussed is CD163; the disease is glioblastoma.